Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2A trial of Ad5.F35-GUCY2C-PADRE vaccine for recurrence prevention in gastrointestinal (GI) adenocarcinomas post definitive surgery and adjuvant therapies.
Authors
Babar Bashir
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, PA
Babar Bashir , Edith P. Mitchell , James Posey , Atrayee Basu Mallick , Daniel Lin , Rajan Singla , Eduardo Fernandez , Michael J. Ramirez , Jagmohan Singh , Walter K. Kraft , Madison Crutcher , Daniel S. Lefler , Benjamin E. Leiby , Tingting Zhan , Scott A. Waldman , Adam E. Snook
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04111172
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS235)
DOI
10.1200/JCO.2024.42.3_suppl.TPS235
Abstract #
TPS235
Poster Bd #
P3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).
First Author: Changying Guo
Poster
2019 ASCO Annual Meeting
Genomic biomarkers of recurrence in low-grade, early-stage endometrial adenocarcinoma.
First Author: Katie Lee Hwang
Poster
2012 ASCO Annual Meeting
Secondary surgery with intraoperative chemo-hyperthermia in recurrent ovarian adenocarcinoma.
First Author: Jean Marc Bereder
Poster
2024 ASCO Breakthrough
Non-invasive minimal residual disease detection of liver cancer using circulating tumor DNA features and α-fetoprotein: A prospective study.
First Author: Yinyin Chang